TEST:

Oncomine Solid Tumor DNA Kit

For patients with a given genetic profile, the melanoma survival and recurrence-free survival rates were equivalent, but not for stage and LDH values. This expanded knowledge of molecular alterations has helped to more comprehensively characterize our patients and has provided relevant information for deciding the best treatment strategy.

These preliminary data suggest a possible prognostic role of TP53 variants in RAS/BRAF wild type mCRC patients receiving first line FOLFIRI/cetuximab followed by Cet alone. Comprehensive genomic profiling is ongoing to identify genomic signatures associated with sensitivity to Cet.

"Conclusion Our preliminary results show good correlation of gene mutation and HPV detection between tumor tissue and baseline LB at initial diagnosis. We will continue patient recruitment and start the analysis of sequential LB after tumor treatment and during follow-up."